Divi’s Labs Rating ‘Buy’; Generic API molecules boost outlook

By: |
March 29, 2021 3:30 AM

Product offerings and better asset utilisation to drive EPS CAGR of 38% over FY20-23; Buy retained with Rs 4,530 TP

Various factors augur well for our expectation of a 21% sales CAGR to Rs 8 bn over FY20–23.Various factors augur well for our expectation of a 21% sales CAGR to Rs 8 bn over FY20–23.

Divi’s Labs (DIVI), in addition to having a robust base business, is enhancing its product offerings in the generic API space – at least sixteen molecules are under various phases of development and in the subsequent DMF filing stage. Particularly, we find DIVI’s work interesting in the Contrast Media segment. While there is complexity associated with Iodine-based products, DIVI’s strong chemistry skill set and experience in the Contrast Media space have enabled it to bring the Iohexol API to the validation phase. We believe DIVI is well-placed to capitalise on the carotenoid opportunity, with a 21% sales CAGR to Rs 8 bn expected over FY20–23. This would be driven by healthy demand, product offerings, integrated manufacturing, and the doubling of capacity.

We continue to value DIVI at 36x 12M forward earnings to arrive at TP of Rs 4,530. We reiterate Buy, encouraged by promising demand prospects and multiple growth levers – (i) new product additions, (ii) a strong chemistry skill set, (iii) efficient manufacturing capabilities, (iv) scale-led advantage in legacy molecules, (v) minimal financial leverage, and (vi) sufficient cash available for new projects.

Iohexol – niche opportunity in Contrast Media space
Contrast media agents have a market size of ~$5 bn. Lower genericisation and limited competition, coupled with DIVI’s specialised chemistry capabilities, provide a reasonable business opportunity. We expect the Iohexal API US market size to be $100–120 m. The genericisation of Omnipaque may provide a potential upside of $40–50 m for DIVI – post the successful validation and subsequent approval for its formulator customer.

Carotenoids – another limited-competition prospect for DIVI
DIVI has fully integrated the Nutraceutical facility (Unit II) for the API/finished form of carotenoids. In fact, it has doubled its capacity over the past year and is well-positioned to benefit from the growing demand for carotenoids. Various factors augur well for our expectation of a 21% sales CAGR to Rs 8 bn over FY20–23.

Reiterate BUY
DIVI has reported ~Rs 25 bn capex since FY18. This has been toward capacity additions as well as to increase backward integration. Considering enhanced product offerings and increased asset utilisation, we expect a 27% sales CAGR over FY20–23. This, coupled with better operating leverage, would drive a 38% earnings CAGR over FY20–23E. Maintain Buy.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Kotak Mahindra AMC gets relief from SAT; tribunal partly stays Sebi order
2Bitcoin-led investments into cryptocurrencies hit record $1.5 billion on the back of first Bitcoin ETF
3Sensex surges for 2nd straight day, Bank Nifty holds above 41200; Nifty eyes 18450 target